<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704156</url>
  </required_header>
  <id_info>
    <org_study_id>ChanghaiHosp</org_study_id>
    <nct_id>NCT02704156</nct_id>
  </id_info>
  <brief_title>SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer</brief_title>
  <official_title>Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib&#xD;
      compared with SBRT plus gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and aim:&#xD;
&#xD;
      Pancreatic cancer is one of the most lethal malignancies and fourth leading cause of cancer&#xD;
      death in both genders in US, where the mortality and incidence increase over the past decade&#xD;
      with a lowest 5-year survival rate of 9% among all cancers. Although surgical resection is&#xD;
      deemed to provide long-term disease control, only 20% patients were candidates for upfront&#xD;
      surgery and unfortunately, even when adjuvant chemotherapy is prescribed, about 50% of&#xD;
      patients will suffer local recurrence. Despite of emergence of immunotherapy as a new&#xD;
      treatment paradigm, little improvement of outcomes has been found in pancreatic cancer. This&#xD;
      may be ascribed to its inherent genetic mutations and immunosuppressive microenvironment. It&#xD;
      has been demonstrated that radiotherapy could enhance the release and uptake of&#xD;
      tumor-associated antigens, thus promoting antitumor T cell priming, and enhancing access to&#xD;
      tumors due to effects both on the tumor vasculature and the chemokine milieu.&#xD;
&#xD;
      Despite of emergence of immune checkpoint inhibitors as a novel treatment paradigm for&#xD;
      cancers, the results of investigations about the efficacy of immunotherapy alone for&#xD;
      pancreatic cancer was disappointing. Due to enhanced immunogenicity of tumor irradiation, the&#xD;
      underlying rationale of combination of radiotherapy and immunotherapy is that radiation can&#xD;
      noninvasively prime the immune system against tumor cells, where antigen presentation and&#xD;
      co-stimulation are facilitated, thus creating immune responses against previously hidden&#xD;
      epitopes that are shared among distant metastases, while immune checkpoint inhibitors can&#xD;
      reverse the immunosuppressive effects of the tumor microenvironment, thus facilitating&#xD;
      antitumor immunity.&#xD;
&#xD;
      Although oncogenic mutations in KRAS are frequent in pancreatic cancer, KRAS proteins are&#xD;
      difficult to be targeted due to high affinity for GTP and/or GDP. Therefore, efforts have&#xD;
      been made to develop therapies targeting the major downstream effector pathways, which&#xD;
      include the RAS-RAF-MEK-ERK and PI3K-PDPK1-AKT signaling pathways. MEK inhibitor trametinib&#xD;
      alone or in combinations with chemotherapy or autophagy inhibitor hydroxychloroquine may&#xD;
      probably have positive effects on tumor regression.&#xD;
&#xD;
      Regarding local recurrence after surgery, it was recommended that chemotherapy with optional&#xD;
      radiotherapy may be the first-line treatment without addition of targeted therapy or&#xD;
      immunotherapy owing to that no studies have investigated the efficacy of this regimen.&#xD;
      Therefore, the aim of our study was to compare the outcomes between stereotactic body&#xD;
      radiation therapy (SBRT) with pembrolizumab and trametinib and SBRT with gemcitabine for&#xD;
      locally recurrent pancreatic cancer after surgical resection.&#xD;
&#xD;
      Study procedure:&#xD;
&#xD;
        1. All surgical specimens underwent immunohistochemical staining of PD-L1, classified as&#xD;
           TC3 ≥ 50% or TC2 ≥ 5% but &lt; 50% or TC1 ≥ 1% but &lt;5% and IC3 ≥ 10% or IC2 ≥ 5% but &lt; 10%&#xD;
           or IC1 ≥ 1% but &lt;5%.&#xD;
&#xD;
        2. KRAS mutations were analyzed by PCR amplification and direct sequencing of exon 2.&#xD;
           Restriction Length Fragment Polymorphism method was used for further confirmation.&#xD;
&#xD;
        3. In the SBRT plus pembrolizumab and trametinib group, 200mg pembrolizumab was&#xD;
           administered intravenously every 3 weeks and 2mg trametinib was given orally once daily.&#xD;
&#xD;
        4. In the SBRT plus gemcitabine group, patients received intravenous gemcitabine&#xD;
           (1000mg/m2) on day 1 and 8 of each 21-day cycle for eight cycles in the absence of&#xD;
           disease progression.&#xD;
&#xD;
        5. The prescribed dose of SBRT varies from 35-40Gy/5f with a single dose of 7-8Gy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Median Survival Time Will be Determined.</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the start of treatment to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One- and Two-year Overall Survival Rate Will be Determined.</measure>
    <time_frame>2 year</time_frame>
    <description>The number of patients alive at 1 year and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Adverse Effects Will be Determined.</measure>
    <time_frame>3 years</time_frame>
    <description>Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Median Progression Free Survival Time Will be Determined.</measure>
    <time_frame>3 years</time_frame>
    <description>The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of patients without disease progressions at 1 year and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life Will be Analyzed.</measure>
    <time_frame>3 years</time_frame>
    <description>The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT plus Pembrolizumab and Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT plus Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyberknife plus Pembrolizumab and Trametinib</intervention_name>
    <description>Radiation therapy plus drug</description>
    <arm_group_label>SBRT plus Pembrolizumab and Trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyberknife plus Gemcitabine</intervention_name>
    <description>Radiation therapy plus drug</description>
    <arm_group_label>SBRT plus Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed pancreatic ductal adenocarcinoma with unequivocal first&#xD;
             progression after surgery followed by chemotherapy&#xD;
&#xD;
          2. Without any immunotherapy or targeted therapy&#xD;
&#xD;
          3. A life expectancy of &gt;3months&#xD;
&#xD;
          4. ECOG of 0 to1&#xD;
&#xD;
          5. Age of 18 years or older&#xD;
&#xD;
          6. Analysis of surgical specimens showed KRAS mutations and positive immunohistochemical&#xD;
             staining of PD-L1&#xD;
&#xD;
          7. Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.5 ×109 cells/L,&#xD;
             leukocyte count≥ 3.5 ×109 cells/L, platelets ≥ 70×109 cells/L, hemoglobin ≥ 8.0 g/dl&#xD;
&#xD;
          8. Liver and kidney function tests: Albumin &gt; 2.5 g/dL, total bilirubin &lt; 3 mg/dL,&#xD;
             creatinine &lt; 2.0 mg/dL, AST&lt;2.5 × ULN(Upper Limit of Normal)(0-64U/L), ALT&lt;2.5 ×&#xD;
             ULN(0-64U/L)&#xD;
&#xD;
          9. INR &lt; 2 (0.9-1.1)&#xD;
&#xD;
         10. Ability of the research subject or authorized legal representative to understand and&#xD;
             the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior immunotherapy or targeted therapy&#xD;
&#xD;
          2. Evidences of metastatic disease confirmed by chest CT or FDG PET-CT&#xD;
&#xD;
          3. Contraindication to receiving immunotherapy, targeted therapy or SBRT&#xD;
&#xD;
          4. ECOG ≥2&#xD;
&#xD;
          5. Age &lt;18 years&#xD;
&#xD;
          6. Analysis of surgical specimens showed KRAS wild type or negative immunohistochemical&#xD;
             staining of PD-L1&#xD;
&#xD;
          7. Secondary malignancy&#xD;
&#xD;
          8. Abnormal results of blood routine examinations and liver and kidney and coagulation&#xD;
             tests&#xD;
&#xD;
          9. Patients with active inflammatory bowel diseases or peptic ulcer&#xD;
&#xD;
         10. Gastrointestinal bleeding or perforation within 6 months&#xD;
&#xD;
         11. Heart failure: NYHA III-IV&#xD;
&#xD;
         12. Respiratory insufficiency&#xD;
&#xD;
         13. Women who are pregnant&#xD;
&#xD;
         14. Participation in another clinical treatment trial while on study&#xD;
&#xD;
         15. Patients in whom fiducial implantation was not possible&#xD;
&#xD;
         16. Inability of the research subject or authorized legal representative to understand and&#xD;
             the willingness to sign a written informed consent document.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huo Jun Zhang, MD., PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.</citation>
    <PMID>32133645</PMID>
  </reference>
  <reference>
    <citation>Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201.</citation>
    <PMID>24104372</PMID>
  </reference>
  <reference>
    <citation>Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009 Sep 1;15(17):5379-88. doi: 10.1158/1078-0432.CCR-09-0265. Epub 2009 Aug 25.</citation>
    <PMID>19706802</PMID>
  </reference>
  <reference>
    <citation>Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NM. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. Epub 2012 May 8.</citation>
    <PMID>22570253</PMID>
  </reference>
  <reference>
    <citation>Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct;33(8):828-33. doi: 10.1097/CJI.0b013e3181eec14c.</citation>
    <PMID>20842054</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.</citation>
    <PMID>22658128</PMID>
  </reference>
  <reference>
    <citation>Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004 Jun 15;64(12):4328-37.</citation>
    <PMID>15205348</PMID>
  </reference>
  <reference>
    <citation>Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.</citation>
    <PMID>26909576</PMID>
  </reference>
  <reference>
    <citation>McCormick F. KRAS as a Therapeutic Target. Clin Cancer Res. 2015 Apr 15;21(8):1797-801. doi: 10.1158/1078-0432.CCR-14-2662. Review.</citation>
    <PMID>25878360</PMID>
  </reference>
  <reference>
    <citation>Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014 Aug 26;111(5):817-22. doi: 10.1038/bjc.2014.215. Epub 2014 Apr 22. Review.</citation>
    <PMID>24755884</PMID>
  </reference>
  <reference>
    <citation>Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). Clin Cancer Res. 2015 Dec 15;21(24):5563-77. doi: 10.1158/1078-0432.CCR-15-0485. Epub 2015 Jul 30.</citation>
    <PMID>26228206</PMID>
  </reference>
  <reference>
    <citation>Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019 Apr;25(4):620-627. doi: 10.1038/s41591-019-0367-9. Epub 2019 Mar 4. Erratum in: Nat Med. 2019 Mar 27;:.</citation>
    <PMID>30833748</PMID>
  </reference>
  <reference>
    <citation>Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. Erratum in: Nat Med. 2020 Jun;26(6):982.</citation>
    <PMID>30833752</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Huo Jun</investigator_full_name>
    <investigator_title>Director of Radiation Oncology Department</investigator_title>
  </responsible_party>
  <keyword>Stereotactic body radiation therapy</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>Initial treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02704156/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment date was from October 2016 to October 2017. Patients were enrolled in our center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SBRT Plus Gemcitabine</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
        </group>
        <group group_id="P2">
          <title>SBRT Plus Pembrolizumab and Trametinib</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SBRT Plus Gemcitabine</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
        </group>
        <group group_id="B2">
          <title>SBRT Plus Pembrolizumab and Trametinib</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="58" upper_limit="73"/>
                    <measurement group_id="B2" value="65" lower_limit="54" upper_limit="74"/>
                    <measurement group_id="B3" value="65" lower_limit="57" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD-L1 intensity</title>
          <description>PD-L1 tumor cell (TC) expression was scored as the percentage of PD-L1 TC, which was stratified as TC3 ≥ 50% or TC2 ≥ 5% but &lt; 50% or TC1 ≥ 1% but &lt;5%. PD-L1 tumor-infiltrating immune cells (IC) expression was scored as the percentage of tumor area stained positive, which was classified as IC3 ≥ 10% or IC2 ≥ 5% but &lt; 10% or IC1 ≥ 1% but &lt;5%. Briefly, the higher expression of TCor IC indicated worse outcomes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IC1 or TC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IC2 or TC2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IC3 or TC3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Median Survival Time Will be Determined.</title>
        <description>The time from the start of treatment to death</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Survival Time Will be Determined.</title>
          <description>The time from the start of treatment to death</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="21.2" upper_limit="23.6"/>
                    <measurement group_id="O2" value="24.9" lower_limit="23.2" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One- and Two-year Overall Survival Rate Will be Determined.</title>
        <description>The number of patients alive at 1 year and 2 years.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>One- and Two-year Overall Survival Rate Will be Determined.</title>
          <description>The number of patients alive at 1 year and 2 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Adverse Effects Will be Determined.</title>
        <description>Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Adverse Effects Will be Determined.</title>
          <description>Treatment-related adverse effects are determined by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 and 4 increased ALT or AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 and 4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 increased blood bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Progression Free Survival Time Will be Determined.</title>
        <description>The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Progression Free Survival Time Will be Determined.</title>
          <description>The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="14.5" upper_limit="16.7"/>
                    <measurement group_id="O2" value="18.3" lower_limit="16.5" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.</title>
        <description>The proportion of patients without disease progressions at 1 year and 2 years.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.</title>
          <description>The proportion of patients without disease progressions at 1 year and 2 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year PFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-year PFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Quality of Life Will be Analyzed.</title>
        <description>The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT Plus Gemcitabine</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
          </group>
          <group group_id="O2">
            <title>SBRT Plus Pembrolizumab and Trametinib</title>
            <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
          </group>
        </group_list>
        <measure>
          <title>The Quality of Life Will be Analyzed.</title>
          <description>The analysis of quality of life is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30). All scales and subscales range from 0 to 100. Regarding physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning and global health, higher scores may indicate better outcomes. In the case of fatigue, nausea and vomitting, pain, dyspnea, insomina, appetite loss, constipation, diarrhea and financial difficulties, lower scores may indicate better outcomes. Scales of all items are independent and not combined to compute a total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="80" upper_limit="93.3"/>
                    <measurement group_id="O2" value="83.7" lower_limit="73.3" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="66.7" upper_limit="100"/>
                    <measurement group_id="O2" value="84.5" lower_limit="66.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="58.3" upper_limit="91.7"/>
                    <measurement group_id="O2" value="72.1" lower_limit="58.3" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="66.7" upper_limit="100"/>
                    <measurement group_id="O2" value="83.3" lower_limit="66.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="83.3" upper_limit="100"/>
                    <measurement group_id="O2" value="84.1" lower_limit="66.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="75" upper_limit="91.7"/>
                    <measurement group_id="O2" value="83.2" lower_limit="75" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="10" upper_limit="43.3"/>
                    <measurement group_id="O2" value="26.6" lower_limit="10" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and vomitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="16.7" upper_limit="50"/>
                    <measurement group_id="O2" value="28.8" lower_limit="0" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="0" upper_limit="50"/>
                    <measurement group_id="O2" value="26.5" lower_limit="16.7" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="13.7" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="17.6" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="0" upper_limit="66.7"/>
                    <measurement group_id="O2" value="33.3" lower_limit="0" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="16.5" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="15.7" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial difficulties</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="17.2" lower_limit="0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SBRT Plus Gemcitabine</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Gemcitabine: Radiation therapy plus drug</description>
        </group>
        <group group_id="E2">
          <title>SBRT Plus Pembrolizumab and Trametinib</title>
          <description>Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.&#xD;
Cyberknife plus Pembrolizumab and Trametinib: Radiation therapy plus drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 and 4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 3 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 vomitting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 3 stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 and 4 increased ALT or AST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 3 increased blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 3 hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 1-2 thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 Nausea and vomitting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 1-2 diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Grade 1-2 stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 increased ALT or AST</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1-2 rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The major limitation of the study was the small number of the randomized patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Huojun Zhang</name_or_title>
      <organization>Changhai Hospital affiliated to Naval Medical University</organization>
      <phone>86-021-31162207</phone>
      <email>chyyzhj@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

